Eisai to open U.S.-based immunodementia discovery center

With a three-year $100 million investment, Eisai Inc. will launch the Eisai Center for Genetics Guided Dementia Discovery in Cambridge, Mass. Eisai Inc. is the U.S. subsidiary of Eisai Co. Ltd. (Tokyo:4523).

The center, expected to open in early 2019, will focus on immunodementia drug discovery guided by genetics research that "go beyond targeting A-beta and tau" for Alzheimer's disease and other dementias...